Know Cancer

or
forgot password

PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations


N/A
18 Years
80 Years
Open (Enrolling)
Both
Newly Diagnosed or Relapsed Acute Myeloid Leukemia

Thank you

Trial Information

PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations


Inclusion Criteria:



- Patients with newly diagnosed or relapsed AML

- AML FAB M0-2, M4-7

- Signed informed consent after patient information

- Male and female patients with AML age 18-80

- 18FDG-PET-CT is available within a period of 5 days after diagnosis of AML

Exclusion Criteria:

- AML FAB M3 (Promyelocytic Leukemia)

- lacking willingness to cooperate

- pregnancy or insufficient contraception

- 18FDG-PET-CT is not available within a period of 5 days after diagnosis of AML

- Medical condition of the patients requires an immediated start of chemotherapy

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Authority:

Germany: Federal Office for Radiation Protection

Study ID:

TUD-PETAML-043

NCT ID:

NCT01278069

Start Date:

February 2011

Completion Date:

May 2015

Related Keywords:

  • Newly Diagnosed or Relapsed Acute Myeloid Leukemia
  • Acute myeloid Leukemia
  • Myeloid Sarcoma
  • Extramedullary Acute myeloid Leukemia
  • 18FDG-PET-CT
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location